Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Biomol Struct Dyn ; 37(6): 1582-1596, 2019 Apr.
Article in English | MEDLINE | ID: mdl-29633917

ABSTRACT

The bacterial ribosome is an established target for anti-bacterial therapy since decades. Several inhibitors have already been developed targeting both defined subunits (50S and 30S) of the ribosome. Aminoglycosides and tetracyclines are two classes of antibiotics that bind to the 30S ribosomal subunit. These inhibitors can target multiple active sites on ribosome that have a complex structure. To screen putative inhibitors against 30S subunit of the ribosome, the crystal structures in complex with various known inhibitors were analyzed using pharmacophore modeling approach. Multiple active sites were considered for building energy-based three-dimensional (3D) pharmacophore models. The generated models were validated using enrichment factor on decoy data-set. Virtual screening was performed using the developed 3D pharmacophore models and molecular interaction towards the 30S ribosomal unit was analyzed using the hits obtained for each pharmacophore model. The hits that were common to both streptomycin and paromomycin binding sites were identified. Further, to predict the activity of these hits a robust 2D-QSAR model with good predictive ability was developed using 16 streptomycin analogs. Hence, the developed models were able to identify novel inhibitors that are capable of binding to multiple active sites present on 30S ribosomal subunit.


Subject(s)
Molecular Docking Simulation , Molecular Dynamics Simulation , Paromomycin/chemistry , Ribosome Subunits, Small, Bacterial/chemistry , Streptomycin/chemistry , Binding Sites , Catalytic Domain , Drug Discovery , Ligands , Microbial Sensitivity Tests , Molecular Structure , Paromomycin/pharmacology , Protein Binding , Quantitative Structure-Activity Relationship , Reproducibility of Results , Sensitivity and Specificity , Streptomycin/pharmacology
2.
Int J Biol Macromol ; 110: 157-166, 2018 Apr 15.
Article in English | MEDLINE | ID: mdl-29410001

ABSTRACT

Lysostaphin (LST) is a bacteriocin that cleaves within the pentaglycine cross bridge of Staphylococcus aureus peptidoglycan. Previous studies have reported the high efficiency of LST even against multi drug resistant S. aureus including methicillin resistant S. aureus (MRSA). In this study, we have developed a new chitosan based hydrogel formulation of LST to exploit its anti-staphylococcal activity. The atomic interactions of LST with chitosan were studied by molecular docking studies. The rheology and the antibacterial properties of the developed LSTC gel were evaluated. The developed LST containing chitosan hydrogel (LSTC gel) was flexible, flows smoothly and remains stable at physiological temperature. The in vitro studies by agar well diffusion and ex vivo studies in porcine skin model exhibited a reduction in S. aureus survival by ∼3 Log10CFU/mL in the presence of LSTC gel. The cytocompatibility of the gel was tested in vitro using macrophage RAW 264.7 cell line and in vivo in Drosophila melanogaster. A gradual disruption of S. aureus biofilms with the increase of LST concentrations in the LSTC gel was observed which was confirmed by SEM analysis. We conclude that LSTC gel could be highly effectual and advantageous over antibiotics in treating staphylococcal-topical and biofilm infections.


Subject(s)
Biofilms/drug effects , Chitosan , Hydrogels , Lysostaphin , Methicillin-Resistant Staphylococcus aureus/physiology , Staphylococcal Infections/drug therapy , Animals , Chitosan/chemistry , Chitosan/pharmacology , Drosophila melanogaster , Humans , Hydrogels/chemistry , Hydrogels/pharmacology , Lysostaphin/chemistry , Lysostaphin/pharmacology , Mice , Molecular Docking Simulation , RAW 264.7 Cells , Staphylococcal Infections/metabolism , Staphylococcal Infections/pathology , Swine
SELECTION OF CITATIONS
SEARCH DETAIL
...